Mr. Thomas Smeenk reports

CYTOIMMUNE SUBSCRIBES FOR 1,634,466 HEMOSTEMIX COMMON SHARES

CytoImmune is subscribing $336,500 (U.S.) to a non-brokered private placement of Hemostemix Inc. common shares at today's closing price of 29.5 cents ($336,500 (U.S.)/69.789 cents (exchange rate) equals $482,167.68) (1,634,466 common shares), subject to the approval of the TSX Venture Exchange, in keeping with its guidance as announced on Jan. 9, 2025.

"The Hemostemix technology transfer was highlighted at CytoImmune's Innovations & Investment in Health and Biotechnology Conference, and this investment is further evidence of our strong and vibrant relationship. Next, at CytoImmune, we plan to present Hemostemix's clinical trial results to Puerto Rico's cardiologists, thoracic surgeons, vascular surgeons, podiatrists, chiropodists and family practitioners. Our objectives are many fold:

1. Treat no-option patients under a special access program;
2. Demonstrate patients' improvements;
3. Track the decrease in health care costs over a health care budget period;
4. Demonstrate to physicians how they can augment their incomes:

For example, a medical practitioner who adds four ACP-01 procedures per day may generates an additional $1-million of income for his practice. One physician who adds four ACP-01 procedures per day generates 80 treatments per month, at $37,000 per unit," president and chief executive officer Thomas Smeenk said.

About Hemostemix Inc.

Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal and cardiomyocyte cell precursors to treat no-option patients worldwide.

We seek Safe Harbor.